Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis

Zheng, Xinhui; Lv, Liwei; Li, Xiangjun; Jiang, Erlie

doi:10.1055/s-0042-1744157

Cited by 1 publication

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,7 Hypomethylating agents (HMAs) such as 5-azacitidine and decitabine, may also be considered preferable treatment options for CMML. 8,9 Nevertheless, HMAs cannot prevent the occurrence of new genetic alterations or transform into AML. 10 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative strategy for CMML.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients withCMML

Zhou,

Wang,

Yuan

et al. 2023

American J Hematol

View full text Add to dashboard Cite

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only curable treatment. The outcomes after transplant are influenced by both disease characteristics and patient comorbidities. To develop a novel prognostic model to predict the post‐transplant survival of CMML patients, we identified risk factors by applying univariable and multivariable Cox proportional hazards regression to a derivation cohort. In multivariable analysis, advanced age (hazard ratio [HR] 3.583), leukocyte count (HR 3.499), anemia (HR 3.439), bone marrow blast cell count (HR 2.095), and no chronic graft versus host disease (cGVHD; HR 4.799) were independently associated with worse survival. A novel prognostic model termed ABLAG (Age, Blast, Leukocyte, Anemia, cGVHD) was developed and the points were assigned according to the regression equation. The patients were categorized into low risk (0–1), intermediate risk (2, 3), and high risk (4–6) three groups and the 3‐year overall survival (OS) were 93.3% (95%CI, 61%–99%), 78.9% (95%CI, 60%–90%), and 51.6% (95%CI, 32%–68%; p < .001), respectively. In internal and external validation cohort, the area under the receiver operating characteristic (ROC) curves of the ABLAG model were 0.829 (95% CI, 0.776–0.902) and 0.749 (95% CI, 0.684–0.854). Compared with existing models designed for the nontransplant setting, calibration plots, and decision curve analysis showed that the ABLAG model revealed a high consistency between predicted and observed outcomes and patients could benefit from this model. In conclusion, combining disease and patient characteristic, the ABLAG model provides better survival stratification for CMML patients receiving allo‐HSCT.

show abstract

Section: Introductionmentioning

confidence: 99%

“…For CMML patients, the standard treatment includes supportive care and cytoreductive therapy 4,7 . Hypomethylating agents (HMAs) such as 5‐azacitidine and decitabine, may also be considered preferable treatment options for CMML 8,9 . Nevertheless, HMAs cannot prevent the occurrence of new genetic alterations or transform into AML 10 …”

Section: Introductionmentioning

confidence: 99%